Third, because this large retrospective cohort did not include reliable RECIST (response evaluation criteria in solid tumors) data [58] for all patients, we did not investigate the correlation between KRAS mutational status and tumor response according to RECIST criteria. The gene discussed is KRAS; the disease is neoplasm.